Context: A polymorphism of the GH receptor (GHR) gene resulting in genomic deletion of exon 3 (GHR-d3) has been associated with responsiveness to GH therapy. However, the data reported so far do vary according to the underlying condition, replacement dose, and duration of the treatment.
G H deficiency (GHD) is heterogeneous in terms of etiology, pathogenesis, and age at diagnosis. Improvement in adult height is the major aim of treating GH-deficient children with recombinant human GH (rhGH) (1) . The final height attained as a result of intervention is influenced, in part, by the dose, injection frequency, and duration of rhGH therapy. Despite optimi-zation of these factors, a proportion of GH-deficient patients do not reach their target height (1, 2) . A number of mathematical models for predicting growth and final outcome has been proposed, enabling the clinician to "personalize" the growth promoting therapy on the grounds of efficacy and economy (2) (3) (4) (5) (6) (7) (8) . However, a range of responsiveness to rhGH exists, even when factors such as statural deficit before treatment, bone "age," midparental height, injection frequency, and dose of rhGH are considered.
It is likely that underlying genetic and epigenetic factors may explain this individual variability of GH response. Based on animal knockout and human mutational analysis, the most likely candidates are factors/genes affecting IGF generation (9) . A polymorphism in the GH receptor (GHR) gene leading to retention [full-length (fl)] or deletion of exon 3 (d3), which encodes a 22-amino acid residue sequence in the extracellular domain (10, 11) , has recently been associated with the degree of height increase in response to GH replacement in children born short for gestational age (SGA), those with idiopathic short stature (ISS) (12) , and in a GH-deficient population (13) . Patients with at least one d3 allele had a significantly better first-year response, leading to an improved adult height on GH treatment than patients with homozygosity for GHR-fl (13) . However, reported studies are not all consistent, which may reflect differing populations and conditions (14 -19) . This makes the application of a pharmacogenetics/genomic approach to therapy problematic.
The aim of this study was to evaluate the impact of the exon-3 GHR genotype on short-term growth response and final height in severely GH-deficient children treated with rhGH. We now report the results of the short-term growth response of 181 severely GH-deficient children treated for 4 yr (study A) according to the exon-3 GHR genotype and, in addition, the results of the long-term growth response of 95 severely GH-deficient children treated to final height (study B).
Subjects and Methods

Subjects
Study A: follow-up of 4 yr [median rhGH; 31.5 g/kg⅐d (range 24 -38); 20 IU/m 2 ⅐wk (range 15-24)]
A total of 181 subjects with severe growth retardation due to isolated GHD (IGHD) was studied. Auxological data are shown in Table 1 . These subjects belonged to 124 nonconsanguineous, unrelated families of Caucasian origin. Diagnostic criteria included a pretreatment height of less than Ϫ3.0 SD score (SDS), decreased height velocity (HV) (Ͻ Ϫ2.5 SDS), retarded bone age (BA), normal karyotype, normal prolactin concentra-tion and thyroid function, and peak GH concentrations less than or equal to 2 ng/ml after two stimulation tests (20 -23) . The remainder of the hypothalamic-pituitary axis tested normal (23) . Standard auxological assessment was performed (21, 22) . None of the affected patients had evidence of an organic disease, psychosocial deprivation, or any eating disorder, and all had normal renal and hepatic function. The BA was estimated according to the methods of Greulich and Pyle (24) and Tanner et al. (25) . No other hormonal deficiency occurred over the study period. Informed consent was obtained from parents and all family members studied. The study was approved by the Clinical Research Ethics Committee.
Study B: up to final height [median rhGH; 27.0 g/kg⅐d (range 24 -31); 17.0 IU/m 2 ⅐wk (range 15-19.5)]
From study A, we identified a subgroup of 95 subjects with severe growth retardation secondary to IGHD, and who had reached final height. Auxological data are shown in Table 2 . These subjects belonged to 63 nonconsanguineous, unrelated families of Caucasian origin. Diagnostic criteria and stimulation tests are described previously. No other hormonal deficiency occurred over the study period. Informed consent was obtained from parents and all family members studied. The study was approved by the Clinical Research Ethics Committee.
Adult control population
A control population composed of 144 healthy adult males recruited at the medical checkup before military service in Switzerland (age range 19 -22 yr), and of 67 healthy women recruited at the University Hospital in Bern, Switzerland (age range 20 -50 yr), was studied. All control subjects were of normal height (Յ 2 and Ն Ϫ2 SDS) (20) . None of the subjects had a family history of pathological short stature, or had received any therapy with rhGH or any other anabolic agent. The study was approved by the Clinical Research Ethics Committee.
Hormonal assays
Pituitary stimulation tests were performed as described previously (23, 26) . Over the years, GH, IGF-I, TSH, LH, FSH, and prolactin were measured using various assays, as previously described. The correlations among the different tests were between r ϭ 0.83 and 0.97.
GH assays
GH was measured using an immunoradiometric assay, HGH MAIAclone (Biodata Diagnostics, Freiburg, Germany), which incorporates two high-affinity monoclonal antibodies. The interassay coefficients of variation were 2.3, 2.4, and 2.2% at 2, 9, and 24 ng/ml, respectively. The intraassay coefficients of variation were 2, 1.7, and 1.7% at 2, 9, and 24 ng/ml. 
IGF-I assays
IGF-I concentrations were determined by either IGF-I kit (Nichols Institute Diagnostics, Bad Vilbel, Germany) or using the assays described by Blum et al. (27) .
DNA isolation and GH-1/GHR gene analysis
Genomic DNA was isolated from peripheral leukocytes of subjects and their relatives (28) . The entire GH-1 gene was sequenced as previously described (29, 30) . For genotyping of the GHR exon-3 locus, a simple multiplex PCR assay was used as previously described (10) . Amplification products were analyzed by electrophoresis on a 1% agarose gel stained with ethidium bromide. GHR-fl allele was detected as a single band corresponding to 935 bp and the GHR-d3 allele corresponding to 532 bp, respectively.
Statistical analysis
Qualitative variables are listed in row numbers, frequencies, as well as in percentages. However, quantitative variables are stated in mean values Ϯ SD. Hardy-Weinberg equilibrium was calculated according to standard procedures using 2 analysis. Differences for GHR-d3/fl genotype frequencies between isolated GH-deficient subjects, controls, and height SDS groups were analyzed by the 2 test. In addition, differences between GHR-d3/fl genotypes for auxological parameters in GH-deficient subjects were assessed using ANOVA Fisher's protected least significant difference test. P values less than 0.05 were considered significant. Furthermore, a multiple linear regression analysis assessing the established influential factors influencing its prognostic significance was performed. All statistical analyses were performed using SigmaStat for Windows (version 3.5; Systat Software UK Ltd., London, UK).
Results
Population studies and GHR-genotype frequencies
To compare the affected families with a normal population, the GHR genotypes in 211 unrelated normal Swiss subjects were analyzed (20) . Individual allele frequencies of controls and parents of isolated GH-deficient subjects were similar in the three height subgroups, and genotype frequencies reached Hardy-Weinberg equilibrium in all the height subgroups studied. Importantly, the genotype frequency of the isolated GH-deficient subjects, as well as the overall control group, was similar, as it was when the genotype frequencies were compared with the overall parental data ( Table 3) .
Study A
All patients showed severe IGHD, and sequencing of the entire GH-1 gene did not reveal any abnormalities. Stimulated GH peaks ranged between 0.3 and 2.0 ng/ml. At the commencement of rhGH replacement therapy, the age of the patients ranged between 4.6 and 9.5 yr. The BA delay ranged between 0.8 and 5.1 yr. Chronological age, BA delay, height SDS, midparental target height SDS, and Tanner-Whitehouse-2 prediction (TW-2) adult height SDS were not statistically different between boys and girls or between GHR genotypes ( Table 1 ).
The first-year HV SDS was significantly higher in subjects with the GHR-d3/d3 genotype when compared with the subjects with the GHR-fl/fl genotype (P Ͻ 0.05) (Table 4 ). Although, overall, patients carrying the GHR-d3/fl genotype when compared with GHR-fl/fl did not present with a statistically different HV SDS (P Ͻ 0.07), a significantly higher HV SDS was, however, observed in patients with one or two copies of GHR-d3 when compared with subjects homozygous for GHR-fl/fl (P Ͻ 0.05); therefore, a GHR-d3 allele dose-dependent effect on HV SDS was found (r ϭ 0.72). In addition, compared with GHR-fl/fl, the height gain after 2-yr treatment expressed in SDS was significantly higher in both girls and boys carrying the GHR-d3/d3 (P Ͻ 0.05) (Table 4 ). Furthermore, the GHR-d3 allele dose-dependent effect was also present (r ϭ 0.77). Although the growth response during the first 2 yr was better in subjects expressing either the GHR-d3/d3 or the GHR-d3/fl genotype, during the third (P Ͻ 0.05: males and females) and fourth (P Ͻ 0.05: females; P Ͻ 0.07: males) year on treatment, the opposite was noted. Finally, subjects with the GHR-d3/d3 genotype showed a trend toward an earlier start of pubertal development. However, this observation was not statistically significant.
Study B
Of the 181 subjects analyzed in study A, 95 reached final height and have been separately analyzed ( Table 2 ). There was no significant difference in adult height and adult height SDS according to the exon-3 genotypes. All subjects independently of their genotype showed slightly lower adult height SDS compared with midparental height SDS (Table 2) .
Therefore, the effect of rhGH replacement therapy at a median dose of 27.0 g/kg⅐d did not reveal any difference between the various genotypes in terms of final height.
Multiple linear regression model
We performed multiple linear regression analysis considering the genotype, chronological age, height SDS at start of replacement therapy, BA, duration of treatment, age at puberty, and GH dose. GHR genotype showed a significant relationship (P Ͻ 0.05) with growth during the first years of replacement therapy, which, however, was not demonstrated at final height (Tables 2  and 4 ). Furthermore, study B (final height study) did not reveal any variables significantly related to HV.
To study the impact of rhGH dose on growth in subjects with IGHD carrying different GHR isoforms, the study population was divided into two groups: group A (n ϭ 95), 52 males and 43 females, rhGH dose 26.5 Ϯ 1.3 (mean Ϯ SD) g/kg⅐d; and group B (n ϭ 86), 46 males and 40 females, rhGH dose 36.5 Ϯ 2.1 g/kg⅐d). Importantly, these two groups, although identical in terms of clinical as well as laboratory findings, do not overlap in terms of rhGH dose used, and, therefore, this separate analysis is statistically valid. A relationship between HV SDS in the firstyear treatment and GHR genotype (homo-and heterozygosity 
Discussion
In this study we analyzed the impact of GHR genotypes (GHR-d3/d3, GHR-d3/fl, and GHR-fl/fl) on growth response to rhGH replacement therapy in patients suffering from severe IGHD (mean maximal GH peak on GH stimulation tests: 0.9 ng/ml). A total of 181 children were followed (study A; Tables 1 and 4 ), and prepubertal HVs during the first 4 yr on rhGH replacement (median dose 31.5 g/kg⅐d) were assessed. In contrast to previous studies, in our study the subjects with the GHR-d3/d3 and GHR-d3/fl were not only pooled but also separately analyzed (13, 18) . Importantly, in the subjects presenting with either GHR-d3/d3 or pooled, so that they had at least one copy of the GHR-d3, an overall significantly better response to the replacement therapy during the first 2-yr therapy was noted, although in the third and fourth year of therapy, this improved HV was observed in those patients with the GHR-fl/fl genotype. In addition, during the first 2 yr on therapy, a GHR-d3 allele-dependent effect on height was found in study A (r ϭ 0.72). However, at final height (study B), the effect of rhGH treatment was identical regardless of the specific GHR genotype. It is worth stressing that the difference between final adult height SDS and the midparental target height SDS in our severely GH-deficient patients was similar to that found in a large cohort of Caucasian GH-deficient children recruited from the Kabi International Growth Study (KIGS) database (31) . Similar data were previously published by the Genentech Growth Study Group (1) underlining the effectiveness of the rhGH treatment used in our studies. From these data also reporting final height, it can be concluded that in severe GH-deficient subjects, the presence or absence of the GHR-d3 allele has no impact on either baseline phenotype or final height, although a difference in response to rhGH replacement therapy during the first years may be observed depending on the genotype. When comparing these findings obtained from patients with severe IGHD with the previous studies focusing on GHR allele genotype and response to rhGH replacement therapy, the patients, individual conditions, their related growth disorder, as well as the rhGH doses used have to be carefully analyzed (12, 14, 16) . In the first report, for instance, Dos Santos et al. (12) studied patients with either SGA or ISS. In this study, patients with normal GH secretion were treated with supraphysiological rhGH replacement doses (12) . Besides the various conditions studied, it is also possible that the differences between the studies reported so far represent the problems of sample size. False-positive findings are more likely with small samples sizes and for quantitative trait loci phenotypical variations tend to be overestimated with small sample sizes (32, 33) . Only large-scale studies of welldefined conditions or pooling data sets will help to resolve these statistical issues. Therefore, it is worth pointing out that our sample size is to our knowledge among the largest reported to date.
Focusing on patients with GHD, Jorge et al. (13) pooled the data obtained from the patients with GHR-d3/d3 and d3/fl and compared their HV with that of patients carrying the GHR-fl/fl genotype. The conclusion drawn from the data were that patients with GHD who were homozygous for GHR-fl responded less well to the rhGH replacement. In addition, in this study 44 GHdeficient patients were also followed up to final height, of whom 22 carried the GHR-fl/fl and the remaining 22 either the d3/d3 or d3/fl genotype. A greater final height was achieved in patients with one or two copies of the GHR-d3 genotype when compared with the patients who were homozygous for the GHR-fl alleles (height SDS Ϫ0.8 vs. Ϫ1.7, respectively). In contrast to our study, in the study of Jorge et al. (13) , not only subjects with IGHD but also combined pituitary hormonal deficiencies were analyzed, and, furthermore, HV data were only presented in prepubertal patients during the first year of treatment. This might at least partly explain the differences obtained. On the contrary, Pilotta et al. (15) could not detect an influence of GHR polymorphisms in the growth response of 54 prepubertal, rhGHtreated children. However, in comparison to our patients, these children had a higher maximal GH increase after stimulation tests (5 Ϯ 2.9 ng/ml). Unfortunately, the authors did not show data analyzing the growth response according to the exon-3 genotype present (15) . In addition, although in the report by Blum et al. (18) the GHR-d3 allele did not affect responsiveness to conventional rhGH replacement therapy, a statistical difference in IGF-I between the genotype groups fl/fl vs. d3/fl and d3/d3 was described. However, this finding could not be reproduced in our study but may underline the notion that responsiveness to GH treatment depends on the functional properties of the GHR. In the original study by Dos Santos et al. (12) , HEK293 fibroblasts were transiently cotransfected with GHR-fl, GHR-d3, or both, and in these experiments, the GHR-d3 induced a higher transcriptional activity of the lactogenic hormone responsive element-luciferase reporter plasmid, which is activated by GH via binding to its GHR. In this study the dose response of GH was studied up to the dose of 50 ng/ml, and the effect in terms of lactogenic hormone responsive element-luciferase activation was described as linear. This increased, and allele dose-dependent responsiveness of the GHR-d3 to rhGH may explain the better growth response during the first years of rhGH treatment in subjects treated with the lower rhGH dose (26.5 vs. 36.5 g/ kg⅐d) as demonstrated using the multiple linear regression models in our study.
Obviously, neither GH responsiveness nor GH sensitivity is constant; the dose-response relationship may vary in every specific condition with/without an underlying growth disorder. Even for a specific condition and dose-response curve, an increase of rhGH dose may well itself affect GHR sensitivity, signaling, and, thus, response to treatment, as is well established in any rhGH-treated child whose response changes after the first years on treatment (2-8). Moreover, the dose response of rhGH differs according to the condition that is treated. For instance, children with GHD, Turner syndrome, SGA, or ISS respond differently (and the rhGH dose is adapted accordingly), but a change in GH sensitivity with treatment remains a variable. Thus, the positive effect resulting from the GHR-d3 genotype may well be down-regulated and/or altered when supraphysiological doses of rhGH are given. This hypothesis could explain why severe GH-deficient subjects might present a rhGH dosedependent GHR genotype-related effect on growth response with an apparent plateau at around 26 g/kg⅐d (16 IU/m 2 ⅐wk), whereas this effect disappears with higher rhGH doses that lie further up on the dose-response curve for this condition. Similarly, SGA children treated with higher doses of rhGH showed no difference in growth response according to the exon-3 genotype in contrast to SGA children treated with lower doses (12, 16) . Duration of GH treatment also seems to play a major role in defining the sensitivity to the GHR genotype, in addition to the etiology of the short stature and its severity. Furthermore, as mentioned by Audi et al. (17) , the GHR-d3/ GHR-fl genotypes may well contribute to the wide range of growth in the normal population. Therefore, we studied 211 healthy Swiss control subjects of both Caucasian original and normal stature (17) . Although the prevalence of the GHR genotypes obtained in our study differs from the Spanish controls, it is of importance, however, to highlight the identical finding that the prevalence of the GHR-d3/d3 and GHR-fl/fl genotypes in the taller subgroup (height of Յ 2 and Ͼ 1 SDS) are respectively higher (13.1 vs. 7.4 and 8%) and lower (39.5 vs. 50 and 48%) when compared with the other two subgroups ( Table 3 ). Similar observations were made when the genotype frequencies of the 248 parents were studied.
In summary, in our two studies focusing on patients with severe IGHD, we observed a GHR-d3 allele dose-dependent effect in subjects treated with rhGH during the first 2 yr, with significantly better responses of either the GHR d3/d3 or the GHR-d3/fl genotype, although no difference was observed at final height. Considering all the studies focusing on IGHD (13, 15, 18, 19) , it becomes clear that the final impact of the GHR genotypes on the rhGH response is minimal. Given the importance of the response to attainment of final height, it may, nevertheless, well be an additional variable having some impact on growth and GH sensitivity, at least at the beginning of rhGH treatment.
